Indian regulator in cahoots with industry and has 'skewed' priorities, says parliament
This article was originally published in Scrip
Executive Summary
In what's perhaps one of the most damning reports on industry and the regulatory mechanism in India in recent times, a parliamentary standing committee on health and family welfare has charged that more than 30 new drugs were approved in the country without undergoing clinical trials.
You may also be interested in...
Expert Panel Affirms ‘Continued Marketing’ Of Ambrisentan, Everolimus In India
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Indian Panel Reviews Celsentri Clearances
An Indian expert panel has sought data on ViiV Healthcare's HIV entry inhibitor maraviroc (Selzentry/Celsentri) - among the drugs cleared, some years ago, with a trial waiver in the country and recommended for re-examination by a Parliamentary committee.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.